Gilead to acquire oral IL-23R inhibitor program from PepStar Therapeutics for $1.275B

Gilead Sciences agreed to acquire the oral IL-23R inhibitor program from privately held PepStar Therapeutics for $1.275 billion in cash, gaining worldwide rights to the program including lead asset HCXT-2001 for inflammatory bowel disease. The deal is expected to close in Q4 2026 and projected to reduce Gilead's fourth-quarter EPS by 79-83 cents.

Detected & updated continuously · Source: Nebula